FILTER
FILTERED INTERVIEW RESULTS
Jorge Nogueira
CEO, DIPHARMA FRANCIS
Dipharma speaks to GBR of how it is adapting to market trends and expanding its geography.
Peter Meath
CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."
Timothy J. Miller
PRESIDENT & CEO, FORGE BIOLOGICS
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
Lesley Millar-Nicholson
DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."
Robert E. Landry
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
Donna LaVoie
PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.
Jeff Reingold
COO, CONTRACT PHARMACAL CORP
Contract Pharmacal Corp explains how it is intends to maintain its organic growth.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios explains its developments in Critical Fluid Inactivation, cannabidiol in the area of cancer-induced peripheral neuropathic pain, and combination therapeutics and methods for the treatment of neurodegenerative diseases.
Dr. Josep Bassaganya-Riera
CHAIRMAN, PRESIDENT AND CEO, LANDOS BIOPHARMA
Landos Biopharma is rapidly developing into an integrated biotech company with a powerful R&D engine and a robust commercial arm.
Scott Bluestein
CEO & CIO, HERCULES CAPITAL
Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Peru Mining 2024 Pre-Release II
As the second half of 2024 approaches, Peru stands at a crossroads. According to the latest figures, the Democratic Republic of Congo has surpassed Peru as the second-largest copper producer. Cabinet changes under Boluarte's administration and ongoing corruption cases have taken a toll on investor confidence, and illegal mining remains a pressing issue. However, not everything is lost for the Andean country, and the mining sector presents growth opportunities.
As the second half of 2024 approaches, Peru stands at a crossroads. According to the latest figures, the Democratic Republic of Congo has surpassed Peru as the second-largest copper producer. Cabinet changes under Boluarte's administration and ongoing corruption cases have taken a toll on investor confidence, and illegal mining remains a pressing issue. However, not everything is lost for the Andean country, and the mining sector presents growth opportunities.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
